Bladder

HCRN-GU22-598

Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder
Status
Cancer Types
Bladder
Locations

HCRN-GU21-551

ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Status
Cancer Types
Bladder
Locations

A Phase II Study of Weekly Paclitaxel and Gemcitabine in Advanced Transitional Cell Carcinoma (TCC) of the Bladder

Status
Cancer Types
Bladder
Locations

A Phase II Study of Weekly Paclitaxel (P) and Gemcitabine (G) in Advanced Transitional Cell Carcinoma (TCC) of the Urothelium)

Status
Cancer Types
Bladder
Locations

A Phase II Study of ALIMTA in Patients with Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

Status
Cancer Types
Bladder
Locations

A Multicenter Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) As First-Line Chemotherapy for Metastatic Urothelial Carcinoma (UC)

Status
Cancer Types
Bladder
Locations

Borealis-2: A randomized phase II study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial cancer (mUC)

Status
Cancer Types
Bladder
Locations

Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC)

Status
Cancer Types
Bladder
Locations

A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer ABATE study

Status
Cancer Types
Bladder
Locations

Urothelial cancer-GENOmic analysis to improve patient outcomes and research (UC-GENOME): a bladder cancer advocacy network (BCAN) led collaborative research study

Status
Cancer Types
Bladder
Locations

A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE)

Status
Cancer Types
Bladder
Locations

Phase 1 trial of durvalumab in combination with BCG or external beam radiation in BCG-unresponsive non-muscle invasive bladder cancer patients

Status
Cancer Types
Bladder
Locations

A phase II trial of atezolizumab (atezo) and bevacizumab (bev) in cisplatin-ineligible patients (pts) with advanced/unresectable urothelial cancer (UC)

Status
Cancer Types
Bladder
Locations

Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188

Status
Cancer Types
Bladder
Locations

Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of HCRN GU14-188

Status
Cancer Types
Bladder
Locations

Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma

Status
Cancer Types
Bladder
Locations

Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC)

Status
Cancer Types
Bladder
Locations

Phase 1b/2 Multicenter Study of Neoadjuvant Pembrolizumab and Chemotherapy for Locally Advanced Urothelial Cancer (NCT02365766)

Status
Cancer Types
Bladder
Locations

Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC)

Status
Cancer Types
Bladder
Locations

Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression

Status
Cancer Types
Bladder
Locations

Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC)

Status
Cancer Types
Bladder
Locations

Phase II trial of gemcitabine and cisplatin plus ipilimumab as first-line treatment for metastatic urothelial carcinoma

Status
Cancer Types
Bladder
Locations

A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB)

Status
Cancer Types
Bladder
Locations

A Phase II Trial of Neoadjuvant Cisplatin (C), Gemcitabine (G), and Sunitinib (S) in Muscle-Invasive Urothelial Carcinoma (miUC)

Status
Cancer Types
Bladder
Locations

Mature results from phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC)

Status
Cancer Types
Bladder
Locations

Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity

Status
Cancer Types
Bladder
Locations

Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium

Status
Cancer Types
Bladder
Locations

Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma

Status
Cancer Types
Bladder
Locations

A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression

Status
Cancer Types
Bladder
Locations

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

Status
Cancer Types
Bladder
Locations

Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Status
Cancer Types
Bladder
Locations

Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

Status
Cancer Types
Bladder
Locations

Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade

Status
Cancer Types
Bladder
Locations

HCRN-GU20-444

Neoadjuvant Pembrolizumab for Muscle-Invasive Bladder Cancer with Selective Bladder Sparing
Status
Open to Accrual
Cancer Types
Bladder
Locations

HCRN-GU14-182

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer: HCRN GU14-182
Status
Closed
Cancer Types
Bladder
Locations

HCRN-GU15-215

A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer
Status
Closed
Cancer Types
Bladder
Locations

HCRN-GU15-217

UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Cancer Research Network GU15-217
Status
Closed
Cancer Types
Bladder
Locations

HCRN-GU15-262

Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Status
Closed
Cancer Types
Bladder
Locations

HCRN-GU16-287

Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer
Status
Open to Accrual
Cancer Types
Bladder
Locations

HCRN-GU17-295

A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma  
Status
Closed
Cancer Types
Bladder
Locations

HCRN-GU17-294

Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade  
Status
Closed
Cancer Types
Bladder
Locations

BTCRC-GU15-023

Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients with Urothelial Cancer (T2-4 N0-2 M0) of the Bladder
Status
Closed
Cancer Types
Bladder
Locations

BTCRC-GU16-051

Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Status
Closed
Cancer Types
Bladder
Locations

GU12-160

The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Cancer Research Network GU12-160
Status
Closed
Cancer Types
Bladder
Locations

GU12-157

A Phase II Trial of Dovitinib in Bacillus Calmette-Guerin(BCG) Refractory Urothelial Carcinoma Patients With Tumor Fibroblast Growth Factor Receptor 3(FGFR3) Mutations or Over-expression: Hoosier Cancer Research Network GU12-157
Status
Closed
Cancer Types
Bladder
Locations

GU10-148

Phase II Trial of Gemcitabine, Cisplatin, Plus Ipilimumab as First-line Treatment for Patients With Metastatic Urothelial Carcinoma: Hoosier Cancer Research Network GU10-148
Status
Closed
Cancer Types
Bladder
Locations

GU10-147

Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147.
Status
Closed
Cancer Types
Bladder
Locations